

Interpretation of mendelian randomization using one measure of an exposure that varies over time.

Tim T Morris * ^{1,2}, Jon Heron^{1,2}, Eleanor Sanderson^{1,2}, George Davey Smith^{1,2}, Kate Tilling^{1,2}.

1. MRC Integrative Epidemiology Unit at the University of Bristol, BS8 2BN, United Kingdom.
2. Population Health Sciences, Bristol Medical School, University of Bristol, Barley House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom.

Corresponding author: Tim T Morris, MRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, BS8 2BN, UK. Email: Tim.Morris@bristol.ac.uk.

Keywords: Mendelian randomization; causal inference; longitudinal; simulation.

Abstract

Background

Mendelian randomization (MR) is a powerful tool through which the causal effects of modifiable exposures on outcomes can be estimated from observational data. Most exposures vary throughout the life course, but MR is commonly applied to one measurement of an exposure (e.g., weight measured once between ages 40 and 60). It has been argued that MR provides biased causal effect estimates when applied to one measure of an exposure that varies over time.

Methods

We propose an approach that emphasises the liability that causes the entire exposure trajectory. We demonstrate this approach using simulations and an applied example.

Results

We show that rather than estimating the direct or total causal effect of changing the exposure value at a given time, MR estimates the causal effect of changing the liability as induced by a specific genotype that gives rise to the exposure at that time. As such, results from MR conducted at different time points are expected to differ (unless the liability of exposure is constant over time), as we demonstrate by estimating the effect of BMI measured at different ages on systolic blood pressure.

Conclusions

Practitioners should not interpret MR results as timepoint-specific direct or total causal effects, but as the effect of changing the liability that causes the entire exposure trajectory. Estimates of how the effects of a genetic variant on an exposure vary over time are needed to interpret timepoint-specific causal effects.

Introduction

Mendelian randomization

Mendelian randomization (MR) is a powerful tool through which the causal effects of modifiable exposures (risk factors) can be estimated from observational data under assumptions that in some circumstances may be more plausible than the unmeasured confounding and no measurement error assumptions required by conventional methods.¹ MR is generally implemented within an instrumental variables (IV) framework that exploits the randomisation inherent in the allocation of genotypes at conception and gamete cell formation, using this random variation in alleles to instrument differences in observed exposures between individuals. Reverse and residual confounding are reduced because formation of genotype occurs prior to phenotypic development and is generally not related to environmental factors.^{2,3}

Three assumptions are required for MR analyses to test the null hypothesis that an exposure X does not cause an outcome Y for any individuals. These are 1) relevance: that genotype is associated with the exposure of interest; 2) independence: that there is no common cause of genotype and outcome; 3) exclusion: that genotype does not affect the outcome through any path other than the exposure.⁴ In order to estimate an average treatment effect (ATE), we additionally assume throughout that the structural model relating IV, exposure(s) and outcome is linear and additive with homogeneous effect of exposure (at every time) on outcome.^{5,6}

MR studies have largely leveraged information from a single measurement of the exposure and outcome, often due to limited availability of repeatedly measured data. Many exposures of interest vary over time,^{7,8} being subject to both between- and within-individual variation. Within-individual variation may be largely a function of measurement error (e.g. height in adulthood⁹), longitudinal within-individual phenotypic variability (BMI¹⁰), monotonic change (myopia¹¹), or likely, a mixture of these. Time-varying genetic associations have been reported for a range of phenotypes¹²⁻¹⁸ and it is therefore unlikely that individuals will follow parallel exposure trajectories across the lifecourse by genotype.^{15,19} Consistent effect sizes may therefore not be estimated when applying MR to exposures that are measured at different time points across the lifecourse, regardless of sampling variation and measurement error.

Mendelian randomization applied to one measure of an exposure that varies over time

It has long been recognised that MR estimates relate to exposures that generally act over a considerable period of time^{1,20} and there is evidence that some SNP-exposure associations are consistent throughout life.²¹ More recently, it has been questioned how appropriate MR is when applied to exposures that vary over time.^{22–24} Labreque & Swanson propose one possible definition of a lifetime effect that might be of interest: the effect of increasing the exposure by one unit at each timepoint throughout the lifecourse.²² In order to estimate this effect using MR, this implies time-invariant exposures and genotype-exposure associations, consistent with parallel exposure trajectories (a one unit change in trajectory at time t will be the same as a one unit change in trajectory at time $t + 1$). They demonstrated that estimates of this causal effect from MR differ over time in the presence of time-varying genotype-exposure associations, concluding that MR provides a biased estimate of the causal effect of increasing the exposure by 1 unit at each timepoint. Concerns have also been raised that MR with time-varying exposures may be biased if a feedback mechanism exists where genetic factors influence predisposition to an outcome, which in turn influences the exposure at a subsequent time point.²³ For example, where instruments for coronary heart disease (CHD) relate to C-reactive protein (CRP) because the instruments for CHD relate to developing atheroma, which in turn increases CRP.


We propose an approach that uses MR to assess the effect on the outcome of the change in the entire exposure trajectory that would be induced by a change in genotype. That is, we are not estimating the causal effect of an exposure as it manifests at a given timepoint, but the effect of the underlying exposure liability. To emphasise that a change in genotype affects all manifestations of the exposure, we introduce a liability L , which is caused by the genotype G , and in turn underlies all the exposure measurements at every instance across the lifecourse. While the effect of liability on outcome is the estimand of interest, the liability is unobserved, so we must estimate its effect via the measured exposures. Here, we consider the case with one genetic instrument (G), two measurements of the time-varying continuous exposure at different occasions (X_0 and X_1), an outcome measured at one timepoint (Y), and an unmeasured confounder U (Figure 1). Thus, a change in genotype changes L , which changes both X_0 and X_1 . The case where X is measured in continuous time is described in the Supplementary Text.

Our approach overcomes two problems with interpretation of MR with time-varying exposures. First, if G changes, both X_0 and X_1 must be changed *together*; a one-unit change in G (e.g., an increase of one risk allele) cannot change one of the exposure measurements in isolation. Where

time-varying genetic effects exist, the change in genotype G required to raise a given exposure trajectory by one unit at time t (e.g., raising weight by 1kg at birth) may be quite different to the change in genotype required to change the exposure by one unit at time $t + k$ (e.g., raising weight by 1kg at age 50). Second, a one-unit change in G cannot have an arbitrary effect on the exposure trajectory (e.g., increase exposure by one unit at all times). Thus, univariable MR with one genetic instrument that acts on exposure over a period of time cannot be used to recover the effect of a change in exposure at a single time, nor of *any arbitrary* change to the trajectory of exposure. Instead, we argue that MR with a time-varying continuous exposure can be used to examine the effect of a *specific* change in the trajectory of that exposure, depending on how genotype impacts the trajectory. Here, the effect refers to the liability L , i.e., we are estimating the effect on the outcome of changing L .

For simplicity, our example has just one SNP causing L . However, L may be proxied by multiple SNPs. The emphasis here is that the effects of X_0 and X_1 cannot be separated in the case where our instrument(s) act through one liability (L). The effects of X_0 and X_1 could potentially be separately estimated within a multivariable MR framework if two or more different liabilities have been identified that have different effects on X_0 and X_1 .

Figure 1: DAG showing two exposures and one outcome. G , genetic instrument; L , liability; X_0 , exposure measured at time 0; X_1 , exposure measured at time 1; Y , outcome; U , confounder. There is a problem of under-identification here in that the direct effects of X_0 or X_1 on Y cannot be estimated with a single liability (L).



In this paper, we clarify the causal quantities that are estimated by MR when applied to time-varying exposures with time-varying genetic effects, and how they should be interpreted.

Methods

Effects of interest

We define two estimands of interest: the total effect of a one-unit change in an exposure X_k (i.e. exposure X measured at a specific timepoint t_k) on an outcome Y (β_{Tk}); and the causal effect on Y of a change in the liability L that is induced by a genetic instrument G , such that X_k increases by one unit as (β_{MRk}). We derive algebraic expressions for these estimands in the case of two time-varying exposures and one outcome, with more general derivations given in Appendix 1.

Total effect


We define β_{Tk} to be the total effect of X_k on an outcome Y , i.e. the change in Y from increasing X_k by one unit. This includes the direct effect of X_k on Y , and the indirect effect via the effect of X_k on subsequent measures of the exposure X_m where $m > k$. Note that with one liability, MR cannot be used to identify the total effect of X_k on Y .

Lifetime liability effect of a specific genotype

We define the liability effect (β_{MRk}) induced by a specific genotype as the causal effect of changing the liability L such that the exposure measured at time t_k is increased by one unit. This can be thought of as the effect of moving an individual from the liability L giving rise to $X = x$ at time t_k , to a liability $L+1$ that would give rise to $X = x + 1$ at time t_k . This is a uniquely defined estimand for the liability associated with a specific genotype; it is the effect on Y of changing L such that X_k increases by one unit. The liability effect of X on Y will be the same for all SNPs associated with the same liability L , but may be different for SNPs that cause a different liability and thus a different trajectory of X .

We now derive expressions for the total and liability causal effect in the situation with an outcome Y that is caused by a genetically influenced exposure X measured at two timepoints (X_0 and X_1) (Figure 2). The genetic instrument G can have a non-linear relationship with the underlying liability L , but we assume linearity and additivity from L to the exposure measurements X_k . The effect of L on exposure measures is allowed to change with age, thus the shape of the trajectory of X with age can be non-linear.

Figure 2: DAG showing the exposure liability in the context of two exposures and one outcome. G , genetic instrument; L , liability; X_0 , exposure measured at time 0; X_1 , exposure measured at time 1; Y , outcome; U , confounder.



The *total effect* of a one unit change in X_0 on Y (β_{T_0}) is given by:

$$\beta_{T_0} = \gamma_4 + \gamma_5\gamma_6$$

The *total effect* of a one unit change in X_1 on Y is given by:

$$\beta_{T_1} = \gamma_6$$

Turning to the liability effect of changes in X_0 and X_1 (β_{G_0}), a one unit increase in X_0 occurs because there is an increase in G from g_{10} to $G = g_{10} + \frac{1}{\gamma_1\gamma_2}$

If $G = g_{10}$ then

$$Y = Y_{10} = g_{10}\gamma_1(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)$$

If $G = g_{10} + \frac{1}{\gamma_1\gamma_2}$ then

$$Y = Y_{20} = \left(g_{10} + \frac{1}{\gamma_1\gamma_2}\right)\gamma_1(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)$$

The effect on Y of changing the liability L such that it raises X_0 by one unit is therefore given by:

$$\beta_{G_{I_0}} = Y_{20} - Y_{10} = \frac{(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)}{\gamma_2} \quad (1)$$

A one unit increase in X_1 would occur because there is an increase in G from g_{11} to $g_{11} +$

$$\frac{1}{\gamma_1(\gamma_2\gamma_5 + \gamma_3)}$$

If $G = g_{11}$ then

$$Y = Y_{11} = g_{11}\gamma_1(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)$$

If $G = g_{11} + \frac{1}{\gamma_1(\gamma_2\gamma_5 + \gamma_3)}$ then

$$Y = Y_{21} = \left(g_{11} + \frac{1}{\gamma_1(\gamma_2\gamma_5 + \gamma_3)}\right)\gamma_1(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)$$

The effect on Y of changing L such that X_1 is increased by 1 unit is given by:

$$\beta_{G_{L_1}} = Y_{21} - Y_{11} = \frac{(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)}{\gamma_2\gamma_5 + \gamma_3} \quad (2)$$

Mendelian Randomisation

We have defined for a given SNP the liability effect (β_{MRk}) as the change in Y induced by raising the liability L such that the value of X measured at time t_k increases by one unit. To reiterate, this represents the causal effect of changing the liability L as induced by the SNP across all individuals such that the exposure at time t_k is increased by one unit. Throughout we use the Wald IV estimator to estimate the effect of liability for an exposure that is induced by a specific genotype.

To estimate the liability effect for a given SNP of X_k on Y with MR using the Wald Ratio (β_{MRk}), we need to calculate the effect of G on Y , and the effect of G on X_k . In our example, we only have two measures of the exposure, so $k=0$ or 1 . For examples with the exposure in continuous time, see the appendix. We now derive the expressions for the liability effect of X_0 and X_1 on Y .

The effect of G on Y is:

$$\beta_{GY} = \gamma_1(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6) \quad (3)$$

The effect of G on X_0 is:

$$\beta_{GX_0} = \gamma_1\gamma_2 \quad (4)$$

The effect of G on X_1 is:

$$\beta_{GX_1} = \gamma_1(\gamma_2\gamma_4 + \gamma_2\gamma_5 + \gamma_1\gamma_3) \quad (5)$$

Using the Wald ratio MR estimate, the change in Y from changing L such that X_0 increases by one unit (the liability effect of a specific genotype) is given by (3)/(4):

$$\beta_{MR_0} = \frac{\gamma_1(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)}{\gamma_1(\gamma_2)} = \frac{(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)}{(\gamma_2)} \quad (6)$$

Therefore, the Wald Ratio MR estimate β_{MR_0} in (6) is equal to the true effect on Y of liability for a one unit change in X_0 in (1), and hence estimates the liability effect of X_0 on Y .

The change in Y from changing L such that X_1 increases by one unit is given by (3)/(5):

$$\beta_{MR_1} = \frac{\gamma_1(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)}{\gamma_1(\gamma_2\gamma_5 + \gamma_3)} = \frac{(\gamma_2\gamma_4 + \gamma_2\gamma_5\gamma_6 + \gamma_3\gamma_6)}{(\gamma_2\gamma_5 + \gamma_3)} \quad (7)$$

Therefore, the Wald Ratio MR estimate in (7) is equal to the true effect on Y of liability for a one unit change in X_1 in (2), and hence estimates the liability effect of X_1 on Y .

MR with a single liability L can therefore only examine whether there is evidence for a causal effect of some measure of the exposure (at some timepoint in the period in which the liability L operates) on the outcome, not which part of the exposure trajectory is causal. It does not matter whether genotype-exposure associations are time-varying or time-invariant; the null hypothesis tested by MR is that the liability L does not cause the outcome, i.e., there is no part of the trajectory which causes the outcome. If the liability does not cause the outcome, a null effect will be correctly estimated by MR.²³ The Wald Ratio MR estimate of the effect of X_k on Y , the *liability effect*, is the effect of increasing L such that X_k increases by 1 unit. We extend this to an outcome measured at multiple timepoints in Appendix 2.

Simulation approach

We describe our simulation approach within the ADEMP framework.²⁵

(A)ims

The aim of the simulation was to evaluate whether the Wald Ratio is an unbiased estimator of the liability effect of X on Y for SNP G

(D)ata-generating mechanisms

We simulated data for 10,000 hypothetical individuals ($n_{obs} = 10,000$), representing a cohort sample with genotypic and phenotypic data collected at two time points (t_0, t_1). Let G represent the genotype of individuals simulated as a single variant (effect alleles = 0,1,2) with minor allele frequency (MAF) set to 0.2 and genotype drawn from this with a binomial distribution. We simulate a time-varying exposure (X_k) for measurement occasions k ($k=0,1$), an outcome measured once (Y), and a time-invariant confounder (U) of exposure and outcome variables. Random measurement error was simulated for all variables except the genetic instrument. Base parameters were set as follows: $\gamma_2: 0.5$; $\gamma_3: 0.5$; $\gamma_4: 0.4$; $\gamma_5: 0.3$; and $\gamma_6: 0.4$; (Figures 2 & 3). All associations with the unobserved confounder were set at 0.3. One-by-one these base parameters were set to zero to investigate the change in coefficient estimated. This allowed us to interrogate differential (i) strength of the genetic instrument; (ii) time-varying genetic associations; (iii) exposure effects on the outcome(s); and (iv) confounding effects. Note that the value of the unbiased estimate will not remain constant but will change depending on the base parameters. Results are presented for 1,000 replications of each simulation. All data were generated within Stata. The programme code used to run the simulations is available at <https://github.com/timtmorris/time-varying-MR> and can be used to vary all parameters.

(E)stimands

We estimate the causal effect of X_k ($k=0,1$) on Y by MR using the Wald ratio, and the standard error (SE) of this parameter in our simulations.


(M)odel

We assess the accuracy of the Wald Ratio MR estimator.

(P)erformance measures

We used three performance measures to assess the estimates in our simulations: the mean of the parameter β , the mean of the parameter SE across 1,000 replications, and the deviation of β from its expectation given the model parameters.

Figure 3: Simulated parameters. G , genotype; L , liability; X_0 , exposure measured at time 0; X_1 , exposure measured at time 1; Y , outcome; U , confounder.



Results

Simulations

Simulations demonstrated that the Wald Ratio MR estimator correctly recovers the liability causal effect in all scenarios with a time-varying exposure, even where time-varying genetic associations existed (γ_2 and γ_3 differ) (Table 1). The estimate of the effect of X_0 on Y is different to that of X_1 on Y . This is because MR is estimating the effect of L on Y rather than the effect of X_k itself i.e., the change in L required to raise X_0 by one unit is 2 ($=1/0.5$), whereas the change in L required to raise X_1 by one unit is 1.54 ($=1/0.65$). Non-zero estimates are recovered for X_0 on Y even when there is no direct path from X_0 to Y . This non-zero coefficient arises because MR provides the causal effect of changing the liability such that the exposure measured at time t_0 is one unit higher, not the effect of a one unit change in X_0 in isolation. It does not matter when the exposures are measured with respect to the outcome (provided that earlier exposures influence the outcome); non-zero effects of X_1 on Y will be correctly estimated even if the exposure is measured after the outcome. This is because one cannot conclude anything about temporality using MR with a single liability. MR recovers unbiased causal effects even where simulations are extended to include outcome-exposure feedback effects or reverse confounding (Appendix 2). Where the liability does not cause exposure during a specific time period (e.g. a genotype may only cause weight gain after puberty), weak instrument bias may affect estimates of the effect of the change in liability required to increase exposure during that period by 1 unit (Table 1, where $\gamma_2 = 0$).²⁶ This bias is smaller for later measures of exposure (Table 1, where $b_1 = 0$) because genetic effects here can operate via earlier measures.

Cross sectional total effects estimated using linear regression are biased even where unobserved confounding from U is absent due to confounding by the liability L that underlies the repeat measures of exposure (Appendix 3).

Table 1: Estimates, standard errors and bias of the liability effect of a time-varying exposure on an outcome using MR. Bias presented as “0.000” where $-0.001 < \text{mean bias} < 0.001$. Note that the rows present the estimate and bias of the *target estimate* when each parameter is changed, not the estimate of the parameter itself.

		Liability effect of:	
		X_0 on Y	X_1 on Y
Estimated liability effect given base parameters in DAG	b (se)	0.92 (0.042)	0.71 (0.031)
Estimated liability effect when setting the following parameter to zero:			
γ_2	b (se)	-83.03 (600000)	0.4 (0.041)
	bias	-83.547	-0.001
γ_3	b (se)	0.52 (0.041)	1.76 (0.206)
	bias	0.002	0.025
γ_4	b (se)	0.52 (0.042)	0.4 (0.028)
	bias	0.002	0.000
γ_5	b (se)	0.8 (0.042)	0.8 (0.042)
	bias	0.003	0.003
γ_6	b (se)	0.4 (0.037)	0.31 (0.031)
	bias	-0.003	-0.001
U	b (se)	0.92 (0.041)	0.71 (0.03)
	bias	0.001	0.000

MR of Body Mass Index measured at different ages on systolic blood pressure using FTO as the instrument

We used two-sample MR to estimate the causal effect of Body Mass Index (BMI) on systolic blood pressure (SBP) using the SNP rs9939609 located in the fat mass and obesity-associated gene (FTO). Note that this single SNP approach prohibited standard 2-sample MR sensitivity analyses but provided a suitable proof of concept. We estimated FTO-BMI associations from a study using data from the 1958 National Survey of Health and Development British cohort at 11 occasions between ages 2 and 53 ($n=2,479$) by Hardy *et al.*¹⁸ We estimated FTO-hypertension associations from a study of Danish individuals in the Copenhagen General Population Study with mean age 57.6 (SD: 13.49) by

Timpson *et al* (n=37,027), thus ensuring no sample overlap.²⁷ All associations were consistent with the study of individuals in the Rotterdam Study (n=5,123) by Labrecque & Swanson.²²


MR results from these SNP-exposure and SNP-outcome associations varied greatly depending on when the exposure was measured (Table 2). This variation in results does not invalidate MR,²² but is expected because the effect of genotype on exposure varied over age (Figure 4). The interpretation of the MR estimate is with respect to the underlying liability. So, from Table 2, the effect of changing the liability caused by FTO such that BMI increases by 1 unit at age 11 would be to increase mid-life blood pressure by 6.08 mmHg (SE: 2.32 mmHg). The effect of changing the liability caused by FTO such that BMI increases by 1 unit at age 53 would be to increase mid-life blood pressure by 12.78 mmHg (SE: 7.77 mmHg). Although these look different, their consistency can be verified by examining Figure 4, and the effect of genotype on BMI at different ages shown in Table 2 – the effect of a 1-unit change in genotype (which would equate to a change in liability) on measured BMI is twice as large at age 11 as at age 53.

MR estimates at different exposure measurement occasions can be converted to the same liability scale provided that SNP-exposure associations at these occasions can be estimated. This conversion can be made by multiplying the Wald Ratio estimate by the SNP-exposure association at its age divided by the SNP- association at another (target) age. Taking FTO-BMI and FTO-hypertension associations from the Hardy *et al* and the Timpson *et al* studies (Table 2), multiplying the age 53 causal effect (12.78 mmHg per SD of BMI) by the SNP-exposure association at age 20 (0.1412) divided by the SNP-exposure association at age 53 (0.0493) gives us the causal effect at age 20 of 4.46 $\left(4.46 = 12.78 \times \frac{0.0493}{0.1412}\right)$. The third column of Table 2 shows the change in G that would be required to raise BMI by one unit at each age. This varies due to variation in SNP-exposure associations at different ages; a one-unit change in BMI corresponds to different genetic effects over time. Given the small size of SNP-exposure associations, particularly at early ages, these values are implausible given the given the range of G . The last column shows the exposure difference induced by the FTO gene at specific ages that would correspond to an FTO-induced BMI difference of one unit at age 20. This information helps to interpret the differing MR estimates and could be used to conduct a GWAS meta-analysis where the exposure was measured at different ages in different studies.

Table 2: Results from MR with time-varying exposures for the causal effect of BMI z-score on SBP using FTO SNP rs9939609. SNP-exposure associations taken from *Hardy et al, 2010*;¹⁸ SNP-outcome association taken from *Timpson et al, 2009*.²⁷ Standard errors for ratio estimates were computed using the formula in *Burgess et al (2017)*²⁸ ignoring covariance between SNP-exposure effects at different ages. BMI, Body Mass Index; SBP, systolic blood pressure; SNP, single nucleotide polymorphism; MR, Mendelian randomization. The SNP-outcome association from *Timpson et al (2009)* was 0.63 (0.153).

Age	SNP-exposure association (SE)	MR estimate (SE)	Change in G required to raise BMI by one unit (SE)	Liability exposure difference equivalent to a one-unit difference in exposure at age 20 (SE)
2	0.013 (0.033)	49.56 (127.47)	78.7 (201.4)	0.09 (0.23)
4	0.019 (0.030)	32.69 (51.68)	51.9 (81.1)	0.14 (0.22)
6	0.0035 (0.031)	178.63 (1546.5)	283.5 (2453.9)	0.025 (0.22)
7	0.043 (0.030)	14.79 (11.18)	23.5 (16.8)	0.30 (0.23)
11	0.104 (0.031)	6.08 (2.32)	9.7 (2.85)	0.73 (0.27)
15	0.107 (0.031)	5.88 (2.23)	9.3 (2.71)	0.76 (0.28)
20	0.141 (0.031)	4.46 (1.46)	7.1 (1.56)	<i>Reference</i>
26	0.097 (0.030)	6.46 (2.52)	10.3 (3.13)	0.69 (0.26)
36	0.070 (0.029)	9.0 (4.30)	14.3 (5.87)	0.50 (0.23)
43	0.043 (0.028)	14.73 (10.30)	23.4 (15.33)	0.30 (0.21)
53	0.049 (0.027)	12.78 (7.77)	20.3 (11.31)	0.35 (0.21)

Figure 4: Effect of an increased risk allele on BMI at different ages from Hardy et al.¹⁸



Discussion

Here we have clarified that MR (using the Wald Ratio estimator) using only one measure of an exposure that varies over time gives a consistent estimate of the causal effect of the liability that underlies the exposure. That is, MR applied to exposures that vary over time estimates the causal effect of the underlying liability rather than the causal effect of the exposure as it manifests at a given measurement occasion. While the effect of liability on outcome is the estimand of interest, the liability is unobserved, so we must estimate its effect via the measured exposures. The MR estimate of the liability effect does not require time-invariant genotype-exposure associations under the assumptions that the structural model is linear and additive, providing that the instruments are valid instruments for the underlying liability.^{8,22} There is also no assumption that the liability L should have the same direction of effect on exposure at all timepoints.²⁹

We have demonstrated that MR estimates the causal effect of having a liability L that gives an exposure value x at time t vs having a liability $L1$ that gives value $x + 1$ at time t . MR with a single genetic proxy of liability cannot therefore be used to infer the direct or total effect of an exposure at

a specific point in time, or to draw inferences about exposure trajectories different to the one L causes (e.g. the effect of increasing exposure by one unit at all timepoints).²² Results from MR conducted at different exposure time points will necessarily differ where time-varying gene-exposure associations exist. However, this does not invalidate MR as previously argued,²² but highlights that it is testing the effect of the liability L on outcome.³⁰ Estimation of time-specific causal effects (i.e. *what is the direct or total effect of the exposure at a given timepoint on the outcome*) will usually not be possible, in the absence of other information.

We proposed a new definition of the “lifetime” causal effect estimated by MR using one measure of a time-varying exposure and one liability as *the causal effect of changing the liability such that the exposure would be one unit higher at a given time*. The estimated “lifetime” causal effect will differ in size if the exposure is measured at a different timepoint, but the estimates will be consistent with the underlying trajectory of exposure induced by the SNP as shown in Table 2. While the FTO trajectories from the study by Hardy *et al*¹⁸ study may differ from those in larger studies,³¹ these have been used for illustrative purposes as they cover a broad range of ages. Our interpretation differs from that previously suggested by Labrecque & Swanson²² in that it rests upon a liability caused by a specific genotype. Labrecque & Swanson argued that MR is sensitive to age-related variation in SNP-exposure associations, whereas we have demonstrated that these differences are a necessary component of time-varying exposures. Our assumption that genotype may act, through liability L , upon the whole lifecourse exposure trajectory³² rather than a single exposure measurement is supported by studies demonstrating time-varying genetic associations.^{12–17} A

It may seem counter-intuitive to use the instrument to describe the causal effect to be estimated – e.g., we are estimating the effect of the liability that is induced by a given SNP. The underlying point is that we can only examine the effect of a liability that has an instrument associated with it. For example, should an analyst wish to estimate the effect of increasing X by 1 unit at all timepoints, an instrument that has a constant effect on exposure over the lifecourse would be required. If the interest is in a liability that causes X to double every 10 years, then an instrument that has this (or a proportional) effect is required. There are thus two consequences of our results. First, that if the aim is to estimate the effect of a specific liability, then the researcher needs to find an instrument for that liability. This is no different to any other situation where some desired exposures cannot be instrumented genetically (e.g., it is hard to imagine a valid genetic instrument for cycling to work). Second, that interpretation of an MR of an exposure that varies over time is with respect to the liability for that exposure that is induced by the given genotype. Thus, interpretation of an MR estimate of a time-varying exposure requires knowledge of the liability induced by the genotype.

Our simulations also demonstrate that MR is not biased by longitudinal exposure mediation, where earlier exposure measures cause later exposure measures. Again, it is not possible to draw inferences on the timing of causal effects because it is the effect of the liability that is being estimated, not just the moment that the exposure was measured. If an outcome affects a later measurement of exposure, an investigator will not incorrectly conclude that the outcome causes the exposure, but they may incorrectly conclude that exposure at *a given age* causes an outcome. With one liability for an exposure, a cumulative effect of exposure will be indistinguishable from an effect of exposure only during specific time periods; one can only say that some part of the exposure trajectory is causal, not *which* part. The lack of ability to determine causal effects at specific timepoints complicates comparisons between MR and RCT's. In an RCT, the timing of exposure (treatment) can be modified, while in MR, randomisation of the liability underlying the exposure trajectory occurs at conception.

While we investigated a single SNP, this interpretation of time-varying MR can in principle be extended to multiple SNPs if they all act on the same underlying liability to exposure (L , in Figure 1). It is however highly unlikely that any two SNPs will induce the same liability and thus the same exposure trajectory (non-causal SNPs which tag the same causal variant would not be seen to *produce* the trajectory). If different SNPs have differing time-varying associations with the exposure, then their estimated liability effects of exposure on outcome will differ. Future studies should assess heterogeneity between groups of SNPs with repeat measures of exposure to assess the consistency of trajectories of exposure.⁸ Assuming multiple liabilities through multivariable Mendelian randomization may allow investigators to more reliably test hypotheses about exposures during different time periods.^{33,34} For example, a recent MR study using multiple instruments with different effects on early (age 10) and later life (age 57) BMI could draw inferences about the different contributions of liability for BMI at ages 10 and 57.¹² An MR study with a single instrument (or multiple instruments acting on the same liability) could only draw inferences on the whole time period acted on by that liability.

Our liability effect assumes a linear, additive structural model, but does not make any assumptions about the timing of how exposure affects the outcome. For example, the exposure may act cumulatively on the outcome, may have sensitive or critical periods,³⁵ or may have different effects depending on its proximity to the outcome window. If the mechanism of exposure is known, then the appropriate summary of exposure could be derived and used in MR. For example, using cumulative exposure or functional principal component analysis to summarise trajectories of

exposure.³⁶ Further longitudinal genetic studies which investigate time-varying genetic associations with exposures are therefore required to better triangulate causal evidence³⁷.

The key aspect when interpreting MR results from time-varying exposures is to consider the underlying liability for a specific exposure trajectory. We have demonstrated this using two exposures for simplicity, but the result holds when the liability is extended across measures of X in continuous time (Appendix 1). MR with a genetic instrument using an exposure measured at a single timepoint provides an unbiased estimate of the causal effect of moving the liability L (as induced by the instrument) such that the exposure at the single timepoint would be predicted to increase by 1 unit. Care must be taken in interpretation of the results of MR analyses using a single measure of a time-varying exposure, as temporal effects cannot be inferred in the presence of a genetic instrument obtained from a single timepoint. It is important for future research to examine the exposure trajectories for every genetic instrument used.²²

Funding

All authors are part of the MRC Integrative Epidemiology Unit (IEU) at the University of Bristol, which is supported by the MRC (MC_UU_00011/5 and MC_UU_00011/3).

Acknowledgements

We thank Tom Palmer for commenting on earlier drafts of this work.

References

1. Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?*. *Int. J. Epidemiol.* **32**, 1–22 (2003).
2. Davey Smith, G. & Hemani, G. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. *Hum. Mol. Genet.* (2014). doi:10.1093/hmg/ddu328
3. Richmond, R. C. & Davey Smith, G. Mendelian randomization: Concepts and scope. *Cold Spring Harb. Perspect. Med.* a040501 (2021).
4. Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. *BMJ* (2018). doi:10.1136/bmj.k601
5. Sheehan, N. A. & Didelez, V. Epidemiology, genetic epidemiology and Mendelian randomisation: more need than ever to attend to detail. *Hum. Genet.* **139**, 121–136 (2020).
6. Labrecque, J. & Swanson, S. A. Understanding the Assumptions Underlying Instrumental Variable Analyses: a Brief Review of Falsification Strategies and Related Tools. *Curr. Epidemiol. Reports* **5**, 214–220 (2018).
7. Labrecque, J. A. & Swanson, S. A. Commentary: Mendelian randomization with multiple exposures: The importance of thinking about time. *International Journal of Epidemiology* (2020). doi:10.1093/ije/dyz234
8. Labrecque, J. A. & Swanson, S. A. Age-varying genetic associations and implications for bias in Mendelian randomization. *medRxiv* (2021). doi:10.1101/2021.04.28.21256235
9. Leon, D. A., Davey Smith, G., Shipley, M. & Strachan, D. Adult height and mortality in London: early life, socioeconomic confounding, or shrinkage? *J. Epidemiol. Community Health* **49**, 5–9 (1995).
10. Tyrrell, J. *et al.* Height, body mass index, and socioeconomic status: mendelian randomisation study in UK Biobank. *BMJ* **352**, i582 (2016).
11. Mountjoy, E. *et al.* Education and myopia: Assessing the direction of causality by mendelian randomisation. *BMJ* (2018). doi:10.1136/bmj.k2022
12. Richardson, T. G., Sanderson, E., Elsworth, B., Tilling, K. & Davey Smith, G. Use of genetic

- variation to separate the effects of early and later life adiposity on disease risk: Mendelian randomisation study. *BMJ* (2020). doi:10.1136/bmj.m1203
13. Mostafavi, H. *et al.* Variable prediction accuracy of polygenic scores within an ancestry group. *Elife* (2020). doi:10.7554/eLife.48376
 14. Simino, J. *et al.* Gene-age interactions in blood pressure regulation: A large-scale investigation with the CHARGE, global BPgen, and ICBP consortia. *Am. J. Hum. Genet.* (2014). doi:10.1016/j.ajhg.2014.05.010
 15. Kwong, A. S. F. *et al.* Polygenic risk for depression, anxiety and neuroticism are associated with the severity and rate of change in depressive symptoms across adolescence. *J. Child Psychol. Psychiatry* **n/a**, (2021).
 16. Warrington, N. M. *et al.* A genome-wide association study of body mass index across early life and childhood. *Int. J. Epidemiol.* (2015). doi:10.1093/ije/dyv077
 17. Jiang, X., Holmes, C. & McVean, G. The impact of age on genetic risk for common diseases. *bioRxiv* (2020). doi:10.1101/2020.07.17.208280
 18. Hardy, R. *et al.* Life course variations in the associations between FTO and MC4R gene variants and body size. *Hum. Mol. Genet.* **19**, 545–552 (2010).
 19. Kwong, A. S. F. *et al.* Genetic and Environmental Risk Factors Associated With Trajectories of Depression Symptoms From Adolescence to Young Adulthood. *JAMA Netw. Open* **2**, e196587–e196587 (2019).
 20. Davey Smith, G. & Ebrahim, S. Mendelian randomization: Prospects, potentials, and limitations. *International Journal of Epidemiology* **33**, 30–42 (2004).
 21. Kivimäki, M. *et al.* Variants in the CRP Gene as a Measure of Lifelong Differences in Average C-Reactive Protein Levels: The Cardiovascular Risk in Young Finns Study, 1980–2001. *Am. J. Epidemiol.* **166**, 760–764 (2007).
 22. Labrecque, J. A. & Swanson, S. A. Interpretation and Potential Biases of Mendelian Randomization Estimates with Time-Varying Exposures. *Am. J. Epidemiol.* (2019). doi:10.1093/aje/kwy204
 23. Burgess, S., Swanson, S. A. & Labrecque, J. A. Are Mendelian randomization investigations

- immune from bias due to reverse causation? *Eur. J. Epidemiol.* (2021). doi:10.1007/s10654-021-00726-8
24. Swanson, S. A., Labrecque, J. & Hernán, M. A. Causal null hypotheses of sustained treatment strategies: What can be tested with an instrumental variable? *Eur. J. Epidemiol.* (2018). doi:10.1007/s10654-018-0396-6
 25. Morris, T. P., White, I. R. & Crowther, M. J. Using simulation studies to evaluate statistical methods. *Stat. Med.* (2019). doi:10.1002/sim.8086
 26. Sanderson, E., Spiller, W. & Bowden, J. Testing and Correcting for Weak and Pleiotropic Instruments in Two-Sample Multivariable Mendelian Randomisation. *bioRxiv* (2020). doi:10.1101/2020.04.02.021980
 27. Timpson, N. J. *et al.* Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using the FTO/MC4R genotype. *Hypertension* **54**, 84–90 (2009).
 28. Burgess, S., Small, D. S. & Thompson, S. G. A review of instrumental variable estimators for Mendelian randomization. *Stat. Methods Med. Res.* **26**, 2333–2355 (2017).
 29. Xue, A. *et al.* Genome-wide analyses of behavioural traits are subject to bias by misreports and longitudinal changes. *Nat. Commun.* **12**, 20211 (2021).
 30. Burgess, S. Identifying the odds ratio estimated by a two-stage instrumental variable analysis with a logistic regression model. *Stat. Med.* **32**, 4726–4747 (2013).
 31. Helgeland, Ø. *et al.* Genome-wide association study reveals dynamic role of genetic variation in infant and early childhood growth. *Nat. Commun.* **10**, 4448 (2019).
 32. Evans, D. M. & Davey Smith, G. Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. *Annu. Rev. Genomics Hum. Genet.* **16**, 327–350 (2015).
 33. Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int. J. Epidemiol.* **48**, 713–727 (2019).
 34. Sanderson, E. Multivariable Mendelian Randomization and Mediation. *Cold Spring Harb. Perspect. Med.* **11**, (2021).

35. Smith, A. D. A. C. *et al.* A structured approach to hypotheses involving continuous exposures over the life course. *Int. J. Epidemiol.* (2016). doi:10.1093/ije/dyw164
36. Cao, Y., Rajan, S. S. & Wei, P. Mendelian randomization analysis of a time-varying exposure for binary disease outcomes using functional data analysis methods. *Genet. Epidemiol.* **40**, 744–755 (2016).
37. Lawlor, D. A., Tilling, K. & Smith, G. D. Triangulation in aetiological epidemiology. *Int. J. Epidemiol.* **45**, 1866–1886 (2016).

Appendices

Appendix 1: Time-varying MR extended to continuous exposure measurements

Lifetime effect

We wish to define a lifetime effect of X_k on Y as the change in Y from changing the entire trajectory of X such that X_k is raised by one unit. However, this is not a uniquely defined estimand – it does not specify how the trajectory of X must be changed, only that the change must be compatible with a one unit rise in X_k . For example, the definition provided by Labreque and Swanson, of a constant one unit increase in X at all times, would be a lifetime effect. Other possible estimands would include the effect of changing just X_k by one unit, whilst keeping all other parts of the trajectory of X constant, or the effect of increasing X_k and all subsequent values of X by one unit. In most practical examples, none of the above estimands could be induced or observed; it is hard to imagine an RCT that could be designed to have such a specific effect on the trajectory of X . Thus, we must define an estimand that does have a natural and uniquely defined estimator.

We define an alternative measure of a lifetime effect as estimated by MR within the context of time-varying exposures; the effect of moving the entire exposure trajectory such that exposure at time t increases by one unit. This differs from the lifetime effect provided by LS, but our definition will be equivalent to theirs under the condition that individual's exposure trajectories differ by the same quantity at every timepoint. We have an outcome Y which is measured only at time T , and an exposure X which is measured continuously, where X_t is the value of X measured at time t .

We define the liability causal effect of shifting the liability L (and thus the entire exposure trajectory) such that X_k becomes $X_k + 1$ at some time k as $E[Y^{X_k} - Y^{\overline{X_k+1}}]$. As in Figure 1, we have a genetic instrument G that acts on the liability L , which then causes X_t . We define the instantaneous effect of X_t on Y by γ_t ; the effect of L on X_t by β_{Lt} ; and the effect of time on X_t by β_{0t} :

$$L = \alpha_0 + \alpha_g G$$

$$X_t = \beta_{0t} + \beta_{Lt} L = \beta_{0t} + \beta_{Lt} (\alpha_0 + \alpha_g G)$$

The effect of the entire trajectory on Y is:

$$E[Y^{\overline{X}}] = \int_0^T \gamma_t x_t dt = \int_0^T \gamma_t (\beta_{0t} + \beta_{Lt} L) dt$$

The change of the whole trajectory such that X_k increases by 1, means adding to L by $\frac{1}{\beta_{Lk}}$

$$E[Y^{\overline{X_{k+1}}}] = \int_0^T \gamma_t \left(\beta_{0k} + \beta_{Lt} \left(L + \frac{1}{\beta_{Lk}} \right) \right) dt$$

Therefore:

$$E[Y^{\overline{X_{k+1}}} - Y^{\overline{X}}] = \int_0^T \frac{1}{\beta_{Lk}} \gamma_t \beta_{Lt} dt = \frac{1}{\beta_{Lk}} \int_0^T \gamma_t \beta_{Lt} dt \quad (A1)$$

We now consider the effect on both X and Y of changes in G . The structural model for X_t when $G = g$ is:

$$E[X_t^g] = \beta_0 + \beta_{Lt}(\alpha_0 + \alpha_g g)$$

Using this in the structural model for $Y^{\overline{X}}$:

$$E[Y^{g=1} - Y^{g=0}] = \int_0^T \gamma_t (\beta_{0t} + \beta_{Lt}(\alpha_0 + \alpha_g g)) dt - \int_0^T \gamma_t (\beta_{0t} + \beta_{Lt}(\alpha_0)) dt$$

Which reduces to:

$$E[Y^{g=1} - Y^{g=0}] = \int_0^T \gamma_t (\beta_{Lt}(\alpha_g)) dt \quad (A2)$$

The structural model for X at time k is:

$$E[X_k^{g=1}] - E[X_k^{g=0}] = \beta_{k0} + \beta_{Lk}(\alpha_0 + \alpha_g) - (\beta_{k0} + \beta_{Lk}(\alpha_0)) = \beta_{Lk}(\alpha_g) \quad (A3)$$

The Wald Ratio estimator is given as the change in the outcome for a given change in the instrument, divided by the change in the exposure for the same change in the instrument. Dividing the reduced form (A2) by the genetic effect measured at time k (A3) we obtain:

$$\frac{E[Y^{g=1} - Y^{g=0}]}{E[X_k^{g=1}] - E[X_k^{g=0}]} = \frac{\int_0^T \gamma_t (\beta_{Lt}(\alpha_g)) dt}{\beta_{Lk}(\alpha_g)} = \frac{1}{\beta_{Lk}} \int_0^T \gamma_t \beta_{Lt} dt$$


This is the same as the causal effect in equation (A1), showing that MR can be interpreted as the lifetime effect of genetically inducing an increase in exposure by one unit at time k .

Appendix 2: MR in the presence of reverse causation

Lifetime effect

Here we consider the case where we have a time-varying outcome (with measures Y_0 and Y_1) and an earlier measure of the outcome causes a later measure of the exposure (Figure A1). We show that the MR estimate is an unbiased estimate of the causal effect of a change in liability L such that there is a one unit change in X at the given time.

Figure A1: DAG showing the liability in the context of two exposures and two outcomes. G , genotype; L , liability; X , exposure; Y , outcome; U , confounder. Subscripts denote timepoint.



For a given G , then the two outcomes are given by:

$$Y_0 = G\gamma_1(\gamma_2\gamma_4)$$

And

$$Y_1 = G\gamma_1(\gamma_2\gamma_4\gamma_9 + \gamma_2\gamma_4\gamma_8\gamma_6 + \gamma_2\gamma_5\gamma_6 + \gamma_2\gamma_7 + \gamma_3\gamma_6)$$

A one unit increase in X_0 occurs because there is an increase from G to $G + \frac{1}{\gamma_1(\gamma_2)}$

The effect on Y_0 of a change in liability L such that there is a one unit change in X_0 is therefore given by:

$$\beta_{G|Y_0X_0} = \frac{1}{\gamma_2}(\gamma_2\gamma_4) \quad (\text{B1})$$

The effect on Y_1 of a change in liability L such that there is a one unit change in X_0 is therefore given by:

$$\beta_{GIY_1X_0} = \frac{1}{\gamma_2} (\gamma_2\gamma_4\gamma_9 + \gamma_2\gamma_4\gamma_8\gamma_6 + \gamma_2\gamma_5\gamma_6 + \gamma_2\gamma_7 + \gamma_3\gamma_6) \quad (\text{B2})$$

A one unit increase in X_1 occurs because there is an increase from g to $g + \frac{1}{\gamma_1(\gamma_2\gamma_5 + \gamma_3 + \gamma_2\gamma_4\gamma_8)}$

The effect on Y_0 of a change in liability L such that there is a one unit change in X_1 is therefore given by:

$$\beta_{GIY_0X_0} = \frac{1}{\gamma_2\gamma_5 + \gamma_3 + \gamma_2\gamma_4\gamma_8} (\gamma_2\gamma_4) \quad (\text{B3})$$

The effect on Y_1 of a change in liability L such that there is a one unit change in X_0 is therefore given by:

$$\beta_{GIY_1X_0} = \frac{1}{\gamma_2\gamma_5 + \gamma_3 + \gamma_2\gamma_4\gamma_8} (\gamma_2\gamma_4\gamma_9 + \gamma_2\gamma_4\gamma_8\gamma_6 + \gamma_2\gamma_5\gamma_6 + \gamma_2\gamma_7 + \gamma_3\gamma_6) \quad (\text{B4})$$

Mendelian Randomisation

To calculate the MR estimate of the effect of X_k on Y using the Wald Ratio, we need to calculate the effect of G on Y , and the effect of G on X_k .

The effect of G on Y_0 is:

$$\beta_{GY_0} = \gamma_1(\gamma_2\gamma_4) \quad (\text{B5})$$

The effect of G on Y_1 is:

$$\beta_{GY_1} = \gamma_1(\gamma_2\gamma_4\gamma_9 + \gamma_2\gamma_4\gamma_8\gamma_6 + \gamma_2\gamma_5\gamma_6 + \gamma_2\gamma_7 + \gamma_3\gamma_6) \quad (\text{B6})$$

The effect of G on X_0 is:

$$\beta_{GX_0} = \gamma_1\gamma_2 \quad (\text{B7})$$

The effect of G on X_1 is:

$$\beta_{GX_1} = \gamma_1(\gamma_2\gamma_5 + \gamma_3 + \gamma_2\gamma_4\gamma_8) \quad (\text{B8})$$

Using the Wald ratio, the MR estimate of an effect on Y_1 from change in liability L such that X_0 increases by one unit is given by (B6)/(B7):

$$\beta_{MRY_1X_0} = \frac{\gamma_1(\gamma_2\gamma_4\gamma_9 + \gamma_2\gamma_4\gamma_8\gamma_6 + \gamma_2\gamma_5\gamma_6 + \gamma_2\gamma_7 + \gamma_3\gamma_6)}{\gamma_1\gamma_2} \quad (B9)$$

Thus, the MR estimate in (B9) is equal to the true effect on Y_1 of liability for a change in liability L such that there is a one unit change in X_0 in (B4).

Similar results follow for the MR estimates of the effect on Y_1 of liability for a change in liability L such that there is a one unit change in X_1 , and on Y_0 of liability for a change in liability L such that there is a one unit change in X_0 or X_1 . Thus, where there is reverse causation, the MR estimates are unbiased estimates of the effect of a change in liability L such that X is one point higher at time k .

Simulations were repeated for two outcome measurements as shown in Figure A2. This additionally allowed us to interrogate differential effects of earlier exposures on later exposures, and reverse causation from earlier outcome measures on later exposure measures.²³

Simulation approach

(A)ims

The aims of the simulations were to evaluate the accuracy with which MR recovers causal estimates of a time-varying exposure on a time-varying outcome.

(D)ata-generating mechanisms

We simulated data for 10,000 hypothetical individuals ($n_{obs} = 10,000$), representing a cohort sample with genotypic and phenotypic data collected at two time points (t_0, t_1). Let G represent the genotype of individuals simulated as a single variant (effect alleles = 0,1,2) with minor allele frequency (MAF) set to 0.2 and genotype drawn from this with a binomial distribution. We simulate a time-varying exposure (X_k) for measurement occasions k , an outcome measured twice (Y_k), and a time-invariant confounder (U) of exposure and outcome variables. Random measurement error was simulated for all variables except the genetic instrument. Base parameters were set as follows: γ_2 : 0.5; γ_3 : 0.5; γ_4 : 0.4; γ_5 : 0.3; γ_6 : 0.4; γ_7 : 0.4; γ_8 : 0.2; and γ_9 : 0.2 (Figure A2) All confounder associations were set to 0.3. One-by-one these base parameters were set to zero to investigate the change in coefficient estimated by MR. This allowed us to interrogate differential (i) strength of the genetic instrument; (ii) time-varying genetic associations; (iii) exposure effects on the outcome(s); and (iv) confounding effects. Note that the value of the unbiased estimate will not remain constant

but will change depending on the base parameters. Results are presented for 1,000 replications of each simulation. All data were generated within Stata. The programme code used to run the simulations is available at <https://github.com/timtmorris/time-varying-MR> and can be used to vary all parameters.

(E)stimands

We assessed the causal effect of X_k on Y_k and the standard error (SE) of this parameter in our simulations.


(M)odel

We assess the accuracy of Instrumental Variables (IV) analyses.

(P)erformance measures

We used three performance measures to assess the estimands in our simulations: the mean of the parameter β , the mean of the parameter SE across 1,000 replications, and the deviation of β from its expectation given the model parameters.

Figure A2: Simulated parameters. G , genotype; L , liability; X_0 , exposure measured at time 0; X_1 , exposure measured at time 1; Y_0 , exposure measured at time 0; Y_1 , exposure measured at time 1; U , confounder.



MR estimates of time-varying exposures in the presence of reverse causation

Simulations demonstrated that MR recovered the correct causal estimate in the presence of time-varying outcomes with outcome-exposure effects (Table A1). Where the parameter X_0X_1 was set to zero, a non-zero effect of 0.91 (SE: 0.04) is correctly estimated for X_0Y_1 . Here, the effect of X_0 on Y_1 operates solely through Y_0 ; both its effect on X_1 and its effect Y_1 .

Table A1: Betas, standard errors, and bias of the liability effect of a time-varying exposure on a time-varying outcome in the presence of reverse causation using MR. Bias presented as “0.000” where $-0.001 < \text{mean bias} < 0.001$. Note that the rows present the estimate and bias of the target estimate when each parameter is changed, not the estimate of the parameter itself.


			Liability effect of:			
			X_0 on Y_0	X_0 on Y_1	X_1 on Y_1	
Estimated causal effect given base parameters in DAG			b (se)	0.4 (0.037)	1.03 (0.044)	0.75 (0.03)
Estimated causal effect when setting the following parameter to zero:						
γ_2	b (se)	0.8 (7031.413)	19.02 (13083.178)	0.4 (0.044)		
	bias	0.395	18.383	-0.001		
γ_3	b (se)	0.4 (0.037)	0.63 (0.043)	1.68 (0.155)		
	bias	-0.001	< +/- 0.001	0.02		
γ_4	b (se)	0 (0.037)	0.92 (0.044)	0.71 (0.031)		
	bias	-0.001	< +/- 0.001	0.001		
γ_5	b (se)	0.4 (0.037)	0.91 (0.044)	0.84 (0.04)		
	bias	< +/- 0.001	-0.001	-0.001		
γ_6	b (se)	0.4 (0.037)	0.48 (0.038)	0.35 (0.03)		
	bias	< +/- 0.001	-0.001	< +/- 0.001		
γ_7	b (se)	0.4 (0.037)	0.63 (0.044)	0.46 (0.028)		
	bias	< +/- 0.001	0.001	-0.001		
γ_8	b (se)	0.4 (0.037)	1 (0.043)	0.77 (0.033)		
	bias	< +/- 0.001	< +/- 0.001	< +/- 0.001		
γ_9	b (se)	0.4 (0.037)	0.95 (0.042)	0.69 (0.029)		
	bias	0.001	0.001	0.001		
U	b (se)	0.4 (0.035)	1.03 (0.042)	0.75 (0.029)		
	bias	-0.002	0.002	0.001		

Appendix 3: Cross-sectional total effects are confounded by genotype

Consider an outcome Y that is caused by two genetically influenced exposures X_0 and X_1 (Figure A3). Here, a linear regression model of Y on X_0 will estimate a biased parameter for the total effect of X_0 even where there is no unobserved confounding from U . This is because the liability underlies the repeat measures of exposure, itself acting as a source of unmeasured confounding between exposure and the outcome. This creates a condition of confounding by common intercept. A linear regression with Y as the dependent variable (outcome) and X_0 as the independent variable (exposure) therefore estimates the total effect of X_0 on Y , which also includes confounding by G . Controlling for the genetic instrument breaks this back door path of confounding in linear regression.

Linear regression estimates applied to time-varying exposures with time-varying genetic effects cannot therefore be interpreted causally, even where unobserved confounding due to traditional sources is not present. There are two circumstances in which this longitudinal confounding by liability may be avoided. First, where every other exposure measure at every other timepoint is conditioned upon, or second, where a causal effect of X_k exists *only* at timepoint k , and X was measured at this time. It is therefore questionable whether linear regression estimates an informative parameter in the presence of time-varying exposures.

Figure A3: DAG showing the liability in the context of two exposures and one outcome. G , genetic instrument; L , liability; X_0 , exposure measured at time 0; X_1 , exposure measured at time 1; Y , outcome; U , confounder.



Simulation approach

(A)ims

The aims of the simulations were to evaluate the accuracy with which MR recovers causal estimates of a time-varying exposure on a time-varying outcome.

(D)ata-generating mechanisms

We simulated data for 10,000 hypothetical individuals ($n_{obs} = 10,000$), representing a cohort sample with genotypic and phenotypic data collected at two time points (t_0, t_1). Let G represent the genotype of individuals simulated as a single variant (effect alleles = 0,1,2) with minor allele frequency (MAF) set to 0.2 and genotype drawn from this with a binomial distribution. We simulate a time-varying exposure (X_k) for measurement occasions k , an outcome measured once (Y), and a time-invariant confounder (U) of exposure and outcome variables. Random measurement error was simulated for all variables except the genetic instrument. Base parameters were set as follows: γ_2 : 0.5; γ_3 : 0.5; γ_4 : 0.4; γ_5 : 0.3; and γ_6 : 0.4 (Figure A4). All confounder associations were set to 0.3. One-by-one we changed the base parameters for b_1 , c and u to zero to investigate the change in coefficient estimated by linear regression. This allowed us to interrogate (i) time-varying and time-invariant genetic associations; and (ii) confounding effects. Results are presented for 1,000 replications of each simulation. All data were generated within Stata. The program code used to run the simulations is available at <https://github.com/timtmorris/time-varying-MR> and can be used to vary all parameters.

(E)stimands

We assessed the total effect of X_0 on Y and the standard error (SE) of this parameter in our simulations.


(M)odel

We assess the accuracy of linear regression analyses under two approaches: (i) where the genetic instrument is omitted from the model; and (ii) where the genetic instrument is included in the model.

(P)erformance measures

We used three performance measures to assess the estimands in our simulations: the mean of the parameter β , the mean of the parameter SE across 1,000 replications, and the deviation of β from its expectation given the model parameters.

Figure A4: Simulated parameters. G , genotype; L , liability; X_0 , exposure measured at time 0; X_1 , exposure measured at time 1; Y , outcome; U , confounder. Parameters in red font are those that were varied.



Cross-sectional total effects are confounded by genotype

Table A2 displays the results of the simulations. Linear regression failed to recover the correct total estimate of X_0Y in the presence of unobserved confounding by U . Where unobserved confounding by U was absent, linear regression only recovered the correct total estimate of X_0Y if the genetic instrument was included in the regression model or there was no confounding by genotype (parameter γ_3 set to zero). This suggests that in the presence of time-varying genetic effects, linear regression will remain biased even where there is no unobserved confounding by traditional sources. Given the complexity of real-world exposure trajectories, this highlights the difficulty of interpreting cross-sectional estimates of a repeat measure exposure.

Table A2: Linear regression estimates, standard errors and bias when estimating the total effect of an exposure on an outcome (X_0Y) using linear regression. Bias presented as “0.000” where $-0.001 < \text{mean bias} < 0.001$.

<i>Confounding by U</i>	<i>G included in analysis model</i>	<i>Parameter set to zero</i>	<i>Expected value</i>	<i>Estimate (SE)</i>	<i>Bias</i>
Absent	No	γ_3	0.52	0.520 (0.010)	0.000
Present	No	γ_3	0.52	0.628 (0.011)	0.108
Absent	Yes	γ_3	0.52	0.519 (0.011)	-0.001
Present	Yes	γ_3	0.52	0.636 (0.011)	0.116
Absent	No	γ_5	0.4	0.429 (0.010)	0.029
Present	No	γ_5	0.4	0.535 (0.011)	0.135
Absent	Yes	γ_5	0.4	0.400 (0.011)	0.000
Present	Yes	γ_5	0.4	0.516 (0.011)	0.116
Absent	No	<i>None</i>	0.52	0.549 (0.010)	0.029
Present	No	<i>None</i>	0.52	0.655 (0.011)	0.135
Absent	Yes	<i>None</i>	0.52	0.520 (0.011)	0.000
Present	Yes	<i>None</i>	0.52	0.636 (0.011)	0.116